149.07
3.53 (2.43%)
| Previous Close | 145.54 |
| Open | 146.00 |
| Volume | 2,009,180 |
| Avg. Volume (3M) | 1,731,362 |
| Market Cap | 23,746,852,864 |
| Price / Sales | 5.06 |
| Price / Book | 15.69 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 - 11 Nov 2024 |
| Profit Margin | -68.73% |
| Operating Margin (TTM) | 22.75% |
| Diluted EPS (TTM) | -19.16 |
| Quarterly Revenue Growth (YOY) | -5.40% |
| Total Debt/Equity (MRQ) | 203.41% |
| Current Ratio (MRQ) | 1.11 |
| Return on Assets (TTM) | 1.43% |
| Return on Equity (TTM) | -76.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Illumina, Inc. | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -1.00 |
|
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.26% |
| % Held by Institutions | 93.30% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 252.00 (RBC Capital, 69.05%) | Buy |
| Median | 164.00 (10.02%) | |
| Low | 135.00 (Barclays, -9.44%) | Hold |
| Average | 174.89 (17.32%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 134.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HSBC | 17 Oct 2024 | 180.00 (20.75%) | Buy | 143.52 |
| Leerink Partners | 17 Oct 2024 | 200.00 (34.17%) | Buy | 143.52 |
| Barclays | 15 Oct 2024 | 135.00 (-9.44%) | Hold | 147.61 |
| 14 Aug 2024 | 125.00 (-16.15%) | Hold | 122.28 | |
| RBC Capital | 10 Oct 2024 | 252.00 (69.05%) | Buy | 143.76 |
| 14 Aug 2024 | 242.00 (62.34%) | Buy | 122.28 | |
| Argus Research | 28 Aug 2024 | 150.00 (0.62%) | Buy | 131.70 |
| Daiwa Capital | 16 Aug 2024 | 154.00 (3.31%) | Buy | 130.31 |
| Scotiabank | 15 Aug 2024 | 164.00 (10.02%) | Buy | 128.80 |
| TD Cowen | 14 Aug 2024 | 144.00 (-3.40%) | Buy | 122.28 |
| Piper Sandler | 13 Aug 2024 | 195.00 (30.81%) | Buy | 119.72 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| THAYSEN JACOB | - | 141.43 | -914 | -129,267 |
| Aggregate Net Quantity | -914 | |||
| Aggregate Net Value ($) | -129,267 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 141.43 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| THAYSEN JACOB | Officer | 05 Oct 2024 | Disposed (-) | 914 | 141.43 | 129,267 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |